2022
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2015
Effects of chemotherapy on quality of life in breast cancer survivors.
Wandell K, Lustberg M, Reinbolt R, Orchard T, Andridge R, Wandell H, Schade C, Moran T, Yang N, Conlan T. Effects of chemotherapy on quality of life in breast cancer survivors. Journal Of Clinical Oncology 2015, 33: 112-112. DOI: 10.1200/jco.2015.33.28_suppl.112.Peer-Reviewed Original ResearchBody mass indexDuke Activity Status IndexQuality of lifeInitiation of treatmentBreast cancer survivorsNutrition-related symptomsFunctional statusCancer survivorsFunctional capacityFirst cycle chemotherapyPG-SGA scoreSubjective Global AssessmentPatients' functional statusDuration of chemotherapyEffect of chemotherapyPeak oxygen uptakeCycle chemotherapyPG-SGAAdjuvant therapySymptom burdenMedian ageMass indexPoor outcomeSignificant changesBreast cancer